Literature DB >> 26125136

Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.

Zonglin Qiu1, Huihui Chong, Xue Yao, Yang Su, Sheng Cui, Yuxian He.   

Abstract

OBJECTIVE: Crystallographic studies of HIV-1 gp41 demonstrate a stable six-helix bundle (6-HB) folded by trimeric N and C-terminal heptad repeats (NHR and CHR), and a deep hydrophobic pocket (pocket-1) on the NHR helices (N-trimer); however, previous crystal structures of 6-HB core were determined by peptide fragments missing the downstream sequence of pocket-1; thus, the structural features of this site could not be observed.
DESIGN: We recently determined several 6-HB structures containing the pocket-1 and its downstream site. Here, we focused to investigate the structural features of N-trimer previously uncharacterized.
METHODS: Biophysical, biochemical and functional approaches were combined to characterize the downstream residues of pocket-1.
RESULTS: A subpocket (designated pocket-2) was visualized on the C-terminal portion of N-trimer, which is formed by a cluster of seven residues, including Leu587, Lys588 and Glu584 on one NHR helix and Tyr586, Val583, Ala582 and Arg579 of another NHR helix. Mutagenesis studies demonstrated that the pocket-2 residues play essential roles for HIV-1 Env-mediated cell entry and critically determine the antiviral activity of NHR-derived peptide fusion inhibitor T21. Further, the pocket-2 mutations dramatically impaired the thermostability and conformation of 6-HB structure and reduced the binding affinity of CHR-derived inhibitor HP23 that specifically targets the deep pocket-1.
CONCLUSION: These data have provided important information for the structure-function relationship of HIV-1 gp41 and for the development of antiviral entry inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26125136     DOI: 10.1097/QAD.0000000000000683

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.

Authors:  Yuanmei Zhu; Xiujuan Zhang; Xiaohui Ding; Huihui Chong; Sheng Cui; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Biol Chem       Date:  2018-02-07       Impact factor: 5.157

3.  Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.

Authors:  Xiyuan Wu; Zixuan Liu; Xiaohui Ding; Danwei Yu; Huamian Wei; Bo Qin; Yuanmei Zhu; Huihui Chong; Sheng Cui; Yuxian He
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

5.  Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.

Authors:  Xiaohui Ding; Xiujuan Zhang; Huihui Chong; Yuanmei Zhu; Huamian Wei; Xiyuan Wu; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

6.  Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

Authors:  S Stenler; K E Lundin; L Hansen; S Petkov; N Mozafari; M Isaguliants; P Blomberg; C I E Smith; D M Goldenberg; C-H Chang; K Ljungberg; J Hinkula; B Wahren
Journal:  Hum Vaccin Immunother       Date:  2017-07-11       Impact factor: 3.452

Review 7.  Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.

Authors:  Jing Pu; Qian Wang; Wei Xu; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

8.  Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.

Authors:  Huihui Chong; Jing Xue; Yuanmei Zhu; Zhe Cong; Ting Chen; Qiang Wei; Chuan Qin; Yuxian He
Journal:  PLoS Pathog       Date:  2019-02-04       Impact factor: 6.823

9.  Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.

Authors:  Xiuzhu Geng; Zixuan Liu; Danwei Yu; Bo Qin; Yuanmei Zhu; Sheng Cui; Huihui Chong; Yuxian He
Journal:  Viruses       Date:  2019-07-03       Impact factor: 5.048

10.  Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.

Authors:  Chao Wang; Xue Li; Fei Yu; Lu Lu; Xifeng Jiang; Xiaoyu Xu; Huixin Wang; Wenqing Lai; Tianhong Zhang; Zhenqing Zhang; Ling Ye; Shibo Jiang; Keliang Liu
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.